TABLE 6.
Anti-HCV efficacy of samatasvir in combination with common anti-HIV or anti-HBV agentsa
| Drug | Target virus(es) (drug class)b | Mean HCV replicon EC50 ± SDc |
Samatasvir fold change | |
|---|---|---|---|---|
| Alone (μM) | With samatasvir (pM)d | |||
| Kaletra | HIV (PI) | ≥114 | 45 ± 8 | 1.9 |
| Zidovudine | HIV (NRTI) | 85.7 | 28 ± 16 | 1.1 |
| Efavirenz | HIV (NNRTI) | ≥172 | 31 ± 8 | 1.3 |
| Raltegravir | HIV (IN) | >143 | 23 ± 6 | 0.9 |
| Lamivudine | HIV, HBV (NRTI) | >241 | 26 ± 6 | 1.0 |
| Tenofovir | HIV, HBV (NRTI) | >237 | 23 ± 6 | 0.9 |
| Telbivudine | HBV (NRTI) | >220 | 28 ± 2 | 1.1 |
a
HCV, hepatitis C virus; HBV, hepatitis B virus.
b
PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; IN, integrase inhibitor.
c
n = 3.
d
The EC50 for samatasvir in the presence of 45% human serum was 25 pM.